Jeffrey H. Hager - Concepedia

Author

Jeffrey H. Hager

University of California, San Francisco

Also Known As

J. H. Hager, J.H. Hager, JEFFREY H. HAGER, Jeffrey H Hager, Jeffrey H. Hager, Jeffrey Hager

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco Edison Pharmaceuticals (United States)UCSF Helen Diller Family Comprehensive Cancer Center Ideaya Biosciences (United States)National Institutes of Health

About

Jeffrey H. Hager is an author at University of California, San Francisco specializing in medicine, cell biology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	2.5K
2	Cell Biology	9	9	1.9K
3	Natural Sciences	3	3	198
4	Biochemistry	1	1	43
5	Diabetes	1	1	246

Jeffrey H. Hager

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment Nicola J. Clegg, John Wongvipat, James D. Joseph, Cancer Research	2012	646
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis Johanna A. Joyce, Amos Baruch, Kareem A. H. Chehade, Cancer Cell Multistage TumorigenesisAngiogenesisCathepsin Cysteine ProteasesInvasive GrowthPathology	2004	627
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509 James D. Joseph, Nhin Lu, Jing Qian, Cancer Discovery	2013	570
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis Masahiro Inoue, Jeffrey H. Hager, Napoleone Ferrara, Cancer Cell Tumor BiologyDevelopmental BiologyAngiogenesisPancreatic CancerMedicine	2002	376
Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas Graeme Hodgson, Jeffrey H. Hager, Stas Volik, Nature Genetics Array CghPancreatic CancerTumor HeterogeneityMedicinePathology	2001	300
Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer Dana E. Rathkopf, Michael J. Morris, Josef J. Fox, Journal of Clinical Oncology	2013	259
Of Mice and MEN1: Insulinomas in a Conditional Mouse Knockout Judy S. Crabtree, Peter C. Scacheri, Jerrold M. Ward, Molecular and Cellular Biology Knockout MouseDevelopmental BiologyPancreatic CancerTumor HeterogeneityConditional Mouse Model	2003	246
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts Andiliy Lai, Mehmet Kahraman, Steven P. Govek, Journal of Medicinal Chemistry Breast OncologyChemoprevention StrategyPharmacotherapyLead Compound 11LTumor Biology	2015	244
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility Jane Guan, Wei Zhou, Marc Hafner, Cell Signal TransductionEndocrine MechanismMedicineHormonal ReceptorReceptor (Biochemistry)	2019	215
Neonatal Hepatitis Induced by α <sub>1</sub> -Antitrypsin: a Transgenic Mouse Model Mark J. Dycaico, Seth G. N. Grant, Katherine A. Felts, Science	1988	142

Page 1